Citius Oncology, Inc. (CTOR) - Form 8-K Summary
Business Context and Reporting Period
Citius Oncology, Inc., a Delaware corporation and emerging growth company, filed this Current Report on Form 8-K on February 13, 2026. The filing serves to announce the Company's results of operations for the first quarter of fiscal 2026. The Company's common stock trades on The Nasdaq Capital Market under the symbol CTOR.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The report explicitly states that the detailed results of operations are contained in a press release furnished as Exhibit 99.1, which is incorporated by reference but not included in the text of this 8-K.
Material Changes
No specific material changes versus the prior comparable period are detailed in the body of this filing. The document acts as a notification that Q1 2026 results have been issued, directing investors to the attached press release for comparative data.
Guidance, Outlook, and Risks
The filing does not contain specific management commentary, forward-looking guidance, risk factors, or details on contingencies and unusual items within the main text. These disclosures are expected to be found in the referenced press release (Exhibit 99.1).
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q1 2026 revenue, net loss, and cash burn figures.
- Verify the Company's cash runway and liquidity position as disclosed in the press release.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the full announcement.
- Confirm if the Company provided updated full-year 2026 financial guidance in the press release.